Pharmaceutical intermediates
Elagolix Sodium Intermediates
5 pharmaceutical intermediates for Elagolix Sodium. Indication: Endometriosis, pain.
About Elagolix Sodium
- Originator
- Neurocrine Biosciences, Inc.
- Indication
- Endometriosis, pain
- Approved Date
- 07/23/2018
- DS/DP
- 07/06/2029
Available intermediates
5 intermediates currently listed for Elagolix Sodium. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| N-[(1R)-2-[(Methylsulfonyl)oxy]-1-phenylethyl]carbamic acid 1,1-dimethylethyl ester | 102089-75-8 | / | / |
| 1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,3H)-dione | 830346-47-9 | / | / |
| 5-Bromo-1-(2-fluoro-6-trifluoromethyl-benzyl)-6- methyl-1H-pyrimidine-2,4-dione | 830346-48-0 | / | / |
| 1-[2-fluoro-6-(trifluoromethyl)benzyl]-5-iodo-6-methylpyrimidine-2,4(1H,3H)-dione | 1150560-54-5 | / | / |
| 5-(2-Fluoro-3-methoxyphenyl)-1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-6-methyl-2,4(1H,3H)-pyrimidinedione | 1150560-59-0 | / | / |
Building toward Elagolix Sodium?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →